Overview

Nasal Human Abuse Potential of PTI-821

Status:
Completed

Trial end date:
2017-12-15

Target enrollment:

Participant gender:

Summary

The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.

Phase:

Phase 1

Details

Lead Sponsor:

Pain Therapeutics

Collaborator:

PRA Health Sciences

Treatments:

Oxycodone